Focused On-demand Library for Protein CBFA2T3

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.







Alternative names:

MTG8-related protein 2; Myeloid translocation gene on chromosome 16 protein; Zinc finger MYND domain-containing protein 4

Alternative UPACC:

O75081; D3DX78; O60615; O60616; O60617; O75082; O75107; O75108; Q0P5Z6; Q6P5W6


Protein CBFA2T3, also known as MTG8-related protein 2, Myeloid translocation gene on chromosome 16 protein, and Zinc finger MYND domain-containing protein 4, plays a crucial role in cellular processes. It acts as a transcriptional corepressor, influencing gene expression by associating with DNA-binding transcription factors. This protein is involved in various cellular functions, including repression of MMP7 expression, regulation of HIF1A protein levels, and modulation of glycolysis and mitochondrial respiration. Additionally, it contributes to the differentiation of erythroid progenitors and granulocyte differentiation.

Therapeutic significance:

Understanding the role of Protein CBFA2T3 could open doors to potential therapeutic strategies. Its involvement in critical cellular processes such as glycolysis, mitochondrial respiration, and cell differentiation highlights its potential as a target for therapeutic intervention in diseases where these processes are dysregulated.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.